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Abstract
Background: Injection drug use (IDU) and heterosexual virus transmission both contribute to the growing mixed HIV
epidemics in Eastern Europe and Central Asia. In Ukraine—chosen in this study as a representative country—IDU-related risk
behaviors cause half of new infections, but few injection drug users (IDUs) receive methadone substitution therapy. Only
10% of eligible individuals receive antiretroviral therapy (ART). The appropriate resource allocation between these programs
has not been studied. We estimated the effectiveness and cost-effectiveness of strategies for expanding methadone
substitution therapy programs and ART in mixed HIV epidemics, using Ukraine as a case study.
Methods and Findings: We developed a dynamic compartmental model of the HIV epidemic in a population of non-IDUs,
IDUs using opiates, and IDUs on methadone substitution therapy, stratified by HIV status, and populated it with data from
the Ukraine. We considered interventions expanding methadone substitution therapy, increasing access to ART, or both. We
measured health care costs, quality-adjusted life years (QALYs), HIV prevalence, infections averted, and incremental cost-
effectiveness. Without incremental interventions, HIV prevalence reached 67.2% (IDUs) and 0.88% (non-IDUs) after 20 years.
Offering methadone substitution therapy to 25% of IDUs reduced prevalence most effectively (to 53.1% IDUs, 0.80% non-
IDUs), and was most cost-effective, averting 4,700 infections and adding 76,000 QALYs compared with no intervention at
US$530/QALY gained. Expanding both ART (80% coverage of those eligible for ART according to WHO criteria) and
methadone substitution therapy (25% coverage) was the next most cost-effective strategy, adding 105,000 QALYs at
US$1,120/QALY gained versus the methadone substitution therapy-only strategy and averting 8,300 infections versus no
intervention. Expanding only ART (80% coverage) added 38,000 QALYs at US$2,240/QALY gained versus the methadone
substitution therapy-only strategy, and averted 4,080 infections versus no intervention. Offering ART to 80% of non-IDUs
eligible for treatment by WHO criteria, but only 10% of IDUs, averted only 1,800 infections versus no intervention and was
not cost effective.
Conclusions: Methadone substitution therapy is a highly cost-effective option for the growing mixed HIV epidemic in
Ukraine. A strategy that expands both methadone substitution therapy and ART to high levels is the most effective
intervention, and is very cost effective by WHO criteria. When expanding ART, access to methadone substitution therapy
provides additional benefit in infections averted. Our findings are potentially relevant to other settings with mixed HIV
epidemics.
Please see later in the article for the Editors’ Summary.
Citation: Alistar SS, Owens DK, Brandeau ML (2011) Effectiveness and Cost Effectiveness of Expanding Harm Reduction and Antiretroviral Therapy in a Mixed HIV
Epidemic: A Modeling Analysis for Ukraine. PLoS Med 8(3): e1000423. doi:10.1371/journal.pmed.1000423
Academic Editor: David D Celentano, Johns Hopkins University, United States of America
Received February 11, 2010; Accepted January 19, 2011; Published March 1, 2011
This is an open-access article distributed under the terms of the Creative Commons Public Domain declaration which stipulates that, once placed in the public
domain, this work may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose.
Funding: This research was supported by Grant Number R01DA15612 from the National Institute on Drug Abuse. Sabina S. Alistar is also supported by a Stanford
Graduate Fellowship. Dr. Owens is supported by the Department of Veterans Affairs. The funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
Competing Interests: DKO received an honorarium from Quintiles to prepare a continuing medical education lecture about HIV screening. No other competing
interests have been declared.
Abbreviations: ART, antiretroviral therapy; CI, confidence interval; IDU, injection drug use; IDUs, injection drug users; QALY, quality-adjusted life year
* E-mail: sabina-alistar@stanfordalumni.org
PLoS Medicine | www.plosmedicine.org 1 March 2011 | Volume 8 | Issue 3 | e1000423Introduction
The HIV epidemics in Eastern Europe and Central Asia have
been rapidly growing over the past decade, mainly due to
increasing injection drug use combined with heterosexual HIV
transmission [1,2]. Among the countries in the region, Ukraine’s
situation has raised serious concerns, since it has one of the fastest
growing HIV epidemics in the world, with newly registered cases
tripling between 1999 and 2007 [3]. With 82,000 officially
registered cases in 2007 and an estimated 395,000 (range:
230,000–573,000) total infected adults, Ukraine’s HIV prevalence
is the highest in Europe [3,4]. The HIV epidemic in Ukraine is
similar to that of other countries in Eastern Europe and Central
Asia [5,6], which makes it an important case study for HIV
interventions.
The epidemic in Ukraine, like other countries in the region, is
still concentrated in at-risk populations, particularly injection drug
users (IDUs), who represented more than 40% of newly registered
infections in 2007 [3]. However, the epidemic seems to now be
transitioning into the general population, raising concerns about
the possibility of a generalized epidemic [7,8]. In 1997, IDUs
accounted for 83.6% of new infections; by 2007, heterosexual
transmission was responsible for 38.4% of registered cases [3].
In 2007, an estimated 390,000 Ukrainians were IDUs; a large
increase in drug use from the previous decade [4] has occurred not
only in Ukraine but in most former USSR states, and was driven
by the economic collapse in the early 1990s and the easy
availability of precursors for injection drugs [7,9]. The most
common substances injected are ‘‘shirka’’ (liquid poppy straw) and
‘‘vint’’ (an ephedrine-based amphetamine) [10,11].
Practices common among IDUs in Ukraine and other countries
in the region (social injecting, syringe sharing, common containers)
increase the risk of transmitting HIV [2,10,12]. Thus, interven-
tions (e.g., needle exchange, bleaching, education) that can limit
these risk factors have been gradually implemented [3]. In
December 2007 Ukraine approved the use of methadone for
substitution therapy, expanding the range of harm reduction
interventions available to those treating IDUs [3,13]. Current
plans aim to enroll 11,000 IDUs in substitution therapy by 2011
[14].
Attempts have been made to increase access to antiretroviral
therapy (ART) among HIV-infected individuals eligible for
treatment, but progress has been limited [1,3]. National Ukrainian
HIV control plans required 90% ART coverage of those eligible
for treatment by WHO criteria (CD4 cell count ,350 cells/ml) by
2010 [15]. However, in 2007 only 7,700 people—less than 10% of
the 91,000 eligible patients—received ART [3,16]. The level of
access to ART for HIV-infected IDUs is unknown, but reports
indicate that physicians are reluctant to treat IDUs, owing to
alleged poor compliance with treatment, and that police confiscate
the antiretroviral medicines when arresting IDUs [11,17–19].
Resources for HIV interventions in the Ukraine are limited.
Hence, balancing investment between methadone substitution
therapy and ART in the most effective way is important. Several
studies have investigated the cost-effectiveness of methadone
substitution therapy in North American and Western European
settings [20–23], but have not considered trade-offs between ART
and methadone substitution therapy. One study evaluated the
cost-effectiveness of harm reduction programs in Odessa, Ukraine
but did not include methadone substitution therapy as an
intervention [24]. The goal of our analysis was to evaluate the
effectiveness and cost-effectiveness of varying levels of investment
in methadone substitution therapy, ART, or both, in Ukraine. The
aim of this study is to help policymakers assess whether
investments in such programs are synergistic, or whether allocating
resources either to methadone substitution therapy or ART is
more effective.
Methods
Overview
To project the evolution of a mixed HIV epidemic under
different intervention strategies, we developed a dynamic com-
partmental model of a population of IDUs on methadone
substitution therapy, IDUs injecting opiates, and non-IDUs
(details in Figure S1; Table S1; Text S1). The model was
parameterized using Ukraine country-level data, and calibrated
against current HIV trends in Ukraine [3,4]. Table 1 summarizes
key model parameters and their sources. Individuals transition
between compartments at rates determined by behavioral and
epidemic characteristics in Ukraine and the natural history of
HIV. We evaluated the costs and quality-adjusted life years
(QALYs) associated with each scale-up strategy and performed
cost-effectiveness analysis. We performed extensive sensitivity
analyses on all parameters.
Strategies Analyzed
In 2008, only 500 of Ukraine’s 400,000 IDUs received
substitution therapy of any kind [3]. Hence, we assumed that no
methadone substitution therapy slots were available in the
comparison case, herein denoted as the status quo; this also serves
as a comparison if methadone substitution therapy is unacceptable
for other reasons (political, social). Reflecting Ukraine data, we
assumed that baseline ART access is 10% for non-IDUs, 2% for
IDUs not receiving methadone substitution therapy, and 25% for
IDUs receiving methadone substitution therapy [3,15,16].
We analyzed incremental strategies that focused on increasing
the number of methadone substitution therapy slots, expanding
access to ART, or both, as summarized in Table 2.
We considered a ‘‘low methadone substitution therapy’’
scenario, the equivalent of Ukraine’s current plans [14] scaled
for our modeled population of 1,000,000 individuals (500
methadone substitution therapy slots, covering 3.1% of IDUs), a
‘‘moderate methadone substitution therapy’’ scenario that assumes
a program that is four times larger (2,000 slots, covering 12.5% of
IDUs), and a ‘‘high methadone substitution therapy’’ scenario
(4,000 slots, reaching 25% of IDUs). We only scaled methadone
substitution therapy up to 25% of IDUs because there is limited
information about the practical aspects of a larger scale
methadone substitution therapy program in Ukraine. Realistically
it is often impractical to assume that such a program can reach a
large number of IDUs effectively, since they are a marginalized
population that avoids contact with authorities and the national
health-care system.
For the ART strategies, we considered a ‘‘low treatment’’
scenario with 20% of eligible patients receiving ART [3], a
‘‘moderate treatment’’ scenario with 50% ART access, and a
‘‘high treatment’’ scenario with 80% ART access. We assumed
that maximum ART access is 80% because some individuals have
poor tolerance for the drugs, display poor adherence, or are
diagnosed too late. For comparison, we considered a ‘‘limited
treatment’’ scenario that provided maximum ART access (80%) to
everyone except IDUs (10% access).
We considered two strategies that improved both methadone
substitution therapy and ART availability: a ‘‘low mixed’’ scenario
(500 methadone substitution therapy slots, 20% ART access), and
a ‘‘moderate mixed’’ scenario (500 methadone substitution
therapy slots, 50% ART access). Finally, we considered a ‘‘high
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both programs would be scaled up to the highest levels we have
considered.
Antiretroviral Therapy
Following international guidelines, we assumed that patients
become eligible for ART when they develop symptomatic HIV
(CD4 between 200–350 cells/ml) or AIDS (CD4 cell count ,200
cells/ml) [25,26]. ART reduces viral load, which leads to lower
infectivity and extended life (slower disease progression and
decreased mortality in the AIDS stage) [27–31]. We assumed
that ART reduces the probability of transmission via risky sexual
contact by 90% [27–31]. The extent to which ART affects
infectivity for equipment sharing is unknown. Similar to previous
work [32,33], we assumed a 50% reduction in the base case
analysis. On the basis of published models of the natural history of
HIV, we assumed that ART reduces by 6-fold the progression rate
from symptomatic HIV to AIDS, and AIDS mortality by 20%
[27–31,34]. Evidence from Ukraine suggests that ART has had a
dramatic effect on AIDS mortality [35].
Methadone Substitution Therapy
No data are available on the effectiveness of methadone
substitution therapy in Ukraine. Pilot programs using buprenor-
phine showed high 6-mo retention rates (75%), and decreases in
IDU risky behaviors to a minimal level [11]. The doses needed for
therapeutic success were lower than in other settings, possibly
reflecting the decreased potency of poppy straw versus heroin [11].
Because methadone substitution therapy is at least as effective as
buprenorphine [20], we assumed that results obtained using
methadone substitution therapy would be similar. We only
considered methadone substitution therapy as an opiate substitute,
since it is more affordable for the same effectiveness and is the
preferred option in countries in the region who decide to
implement substitution therapy [2,36].
We assumed that IDUs receiving methadone substitution
therapy reduced equipment sharing by 85%, and had a higher
likelihood of receiving ART (25% access, versus 2% access for
IDUs not receiving methadone substitution therapy) [11,20]. Since
complete rehabilitation after stopping methadone substitution
therapy is difficult to achieve and many individuals return to
Table 1. Key parameter values, ranges, and sources.
Parameter Value Range Source
Prevalence
HIV prevalence IDUs 41.2% 17.3%–70.0% [3,4]
HIV prevalence non-IDUs 0.99% 0.73%–1.16% Calculated
ART
Access to ART – eligible non-IDUs 10% 7.0%–11.0% [13,16]
Access to ART – eligible IDUs 2% 0.0%–5.0% Estimated [10,12]
Access to ART – eligible IDUs on methadone substitution therapy 25% 0.0%–30.0% Estimated [11,46]
Methadone substitution therapy program
Methadone substitution therapy retention, 6 mo 75% 50.0%–90.0% [11,46]
Percentage methadone substitution therapy ‘‘graduation’’ 5% 1.0%–7.0% [11,46]
Injection behavior
Number of injections per year 250 200–300 [10,12,24,33,39]
Percent of shared injections 25% 10.0%–40.0% [10,12,24,33,39]
Percent decrease in needle sharing due to methadone substitution therapy 85% 60.0%–99.0% [11,20,38,46]
Transmission reduction needle sharing due to ART 50% 10.0%–90.0% [33]
Sexual behavior
Number of sexual partners per year – IDUs 4.3 1.5–4.5 [24,33]
Number of sexual partners per year – non IDUs 1.3 1–1.8 [24,33]
Percentage sexual contacts shared by IDUs with IDUs 45% 20.0%–70.0% [10,12,24,33,40]
Condom usage rate – IDUs not on methadone substitution therapy 40% 20.0%–60.0% [10,12,24,33,40]
Condom usage rate – IDUs on methadone substitution therapy 45% 25.0%–65.0% [10,12,24,33,40]
Condom usage rate – non-IDUs 45% 30.0%–70.0% [10,12,24,33,40]
Condom effectiveness 90% 85.0%–95.0% [23,33,38,56]
Sexual transmission reduction if on ART 90% 50.0%–99.0% [27,33,34]
Annual costs (US$)
Non-HIV medical costs 311 200–450 [16]
HIV costs 1,200 800–1,600 Estimated [3]
ART cost - IDUs not on methadone substitution therapy + IDU services 950 750–2,500 Unpublished data and [33,47,48]
ART cost - IDUs on methadone substitution therapy + IDU services 750 550–2,300 Unpublished data and [33,47,48]
ART cost - non-IDUs 450 250–2,000 Unpublished data and [33,47,48]
Methadone substitution therapy regimen cost + counseling services 368 200–500 [25,39]
doi:10.1371/journal.pmed.1000423.t001
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ceasing methadone substitution therapy stopped injecting drugs.
Model Structure
We considered a population of 1,000,000 individuals aged 15–
49; most new HIV infections, as well as injection drug use, occur
in this age group [3,4]. We segmented the population into 18
compartments distinguished by drug usage status (IDUs receiving
methadone substitution therapy, IDUs injecting opiates, and non-
IDUs), HIV disease stage (uninfected, nonsymptomatic HIV,
symptomatic HIV, or AIDS), and ART access (on treatment, not
on treatment) (Table S2). Reflecting data from Ukraine, in the
base case 1.6% of the adult population were IDU, with 41.2%
initial HIV prevalence [3,4]. Initial HIV prevalence in the non-
IDU population was 0.99% (consistent with the overall population
prevalence of 1.63%). The initial population distribution (Table 3)
was computed starting from the 1,000,000 population and
applying the percentages in Table 1 to obtain the fraction of
individuals who are IDUs and the fraction in each disease stage.
Rates of Drug Use and Mortality
Individuals enter the population at age 15 uninfected with HIV
in IDU compartments (2% of new entries, consistent with the
proportion of the population in IDU [33]) and non-IDU
compartments. We assumed that IDUs have a 1% yearly chance
of spontaneously quitting drugs [37,38]. There is no official
information about the yearly incidence of drug usage in Ukraine.
To model the rate of drug usage uptake, we used an annual rate of
0.0003, consistent with values used in previous analyses [23,38]
and consistent with measured HIV prevalence trends and the
proportion of IDUs in the population. Individuals can die of non-
AIDS–related causes (all compartments) or AIDS (AIDS com-
partments). Death rates from non-AIDS causes were higher for
IDUs than non-IDUs, since IDUs have more risk factors
(overdose, other health consequences of injection drug use). At
age 49, individuals mature out of the population. The total
population size decreased over time, reflecting the negative growth
trend in Ukraine.
HIV Transmission and Progression
We considered HIV transmission via sexual contacts (all
individuals) and equipment sharing (IDUs). We estimated the risk
of acquiring HIV from risky injections for an uninfected IDU on
the basis of annual number of injections, percentage of injections
involving shared equipment, the likelihood of sharing with an
HIV-infected individual, and the probability of HIV transmission
per risky contact. Contact infectivity depended on the disease and
ART status of the infected individual; both affect viral load
Table 2. Key parameters (methadone substitution therapy slots and ART access by population) for strategies considered.
Parameter
Status
Quo
Low
Methadone
Substitution
Moderate
Methadone
Substitution
High
Methadone
Substitution
Low
Mixed
Moderate
Mixed
Low
ART
Moderate
ART
High
ART
Limited
ART
High
Methadone
Substitution
High ART
Methadone substitution
therapy slots
0 500 2,000 4,000 500 500 0 0 0 0 4,000
ART access
IDUs not on methadone
substitution therapy
2% 2% 2% 2% 20% 50% 20% 50% 80% 10% 80%
IDUs on methadone
substitution therapy
0% 25% 25% 25% 25% 50% 0% 0% 0% 0% 80%
Non-IDUs 10% 10% 10% 10% 20% 50% 20% 50% 80% 80% 80%
Description of strategies: Status quo, no methadone substitution therapy slots, 10% of eligible non-IDUs on ART, 2% of eligible IDUs on ART; low methadone
substitution therapy, 3.1% of IDUs on methadone substitution therapy, ART according to status quo except 25% of eligible IDUs on methadone substitution therapy on
ART; moderate methadone substitution therapy, 12.5% of IDUs on methadone substitution therapy, ART according to status quo except 25% of eligible IDUs on
methadone substitution therapy on ART; high methadone substitution therapy, 25% of IDUs on methadone substitution therapy, ART according to status quo except
25% of eligible IDUs on methadone substitution therapy on ART; low mixed, 3.1% of IDUs on methadone substitution therapy, 20% of eligible non-IDUs and IDUs not on
methadone substitution therapy on ART, 25% of IDUs on methadone substitution therapy on ART; moderate mixed, 3.1% of IDUs on methadone substitution therapy,
50% of all eligible patients on ART; low ART, no methadone substitution therapy slots, 20% of all eligible patients on ART; moderate ART, no methadone substitution
therapy slots, 50% of all eligible patients on ART; high ART, no methadone substitution therapy slots, 80% of all eligible patients on ART; limited ART, no methadone
substitution therapy slots, 80% of eligible non-IDUs on ART, 10% of eligible IDUs on ART; high methadone substitution therapy, high ART, 25% of IDUs on methadone
substitution therapy, 80% of all eligible patients on ART.
doi:10.1371/journal.pmed.1000423.t002
Table 3. Initial population distribution for the model.
Population
Group Uninfected Early Infection
Late Infection,
Untreated AIDS, Untreated
Late Infection,
Treated AIDS, Treated
IDUs 9,408 (0.941%) 4,944 (0.494%) 969 (0.097%) 646 (0.065%) 20 (0.0020%) 13 (0.0013%)
General
population
974,292 (97.43%) 7,281 (0.728%) 1,311 (0.131%) 874 (0.087%) 146 (0.015%) 97 (0.010%)
Distribution of a population of 1,000,000 individuals: 1.6% of the total population is IDU; 75% of infected individuals are in the early HIV infection stage; 15% in the late
stage; and 10% have AIDS; 10% of eligible non-IDUs and 2% of eligible IDUs are in treatment.
doi:10.1371/journal.pmed.1000423.t003
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frontloading and backloading of syringes, needle-sharing, and
shared container use, which are reported commonly among
Ukrainian IDUs [10,11,12,39].
For sexual transmission, we considered the average number of
annual new partnerships, which is typically higher for IDUs than
non-IDUs [24,39]. We assumed random mixing in sexual
partnerships, but IDUs preferentially paired with other IDUs:
we assumed that 45% of the time the chosen sexual partner of an
IDU is another IDU, accounting for behavior observed in Ukraine
[12,24,40]. We estimated the annual risk of transmission to an
uninfected individual per partnership on the basis of disease stage
of partner, condom usage rate, and condom effectiveness.
Disease progression for infected individuals occurred at rates
established by HIV natural history models [34]. Transitions
between disease stages occurred at the same rate for IDUs
(including those on methadone substitution therapy) and non-
IDUs, but we accounted for changes caused by ART (extended
life, lower mortality, decreased infectivity) [29,31,34].
Model Calibration
We performed several analyses to verify the outputs of our
model and ensure that the population dynamics accurately reflect
the trends observed in data collected from Ukraine. Without any
interventions, our model predicted a slow decline in both the total
population (matching the recorded demographic trends in
Ukraine) and the prevalence of injection drug use. Our model
predicted a sharp increase in HIV prevalence in IDUs (Figure 1),
and a slower progression of HIV in the general population
(Figure 2), followed by a long-term decline, since HIV-infected
individuals die quickly in the absence of adequate treatment.
Estimates of HIV prevalence in Ukraine vary and there is limited
information about prevalence in specific risk groups. Our model
was calibrated against registered total prevalence trends [3,11].
Recent efforts to increase outreach to most-at-risk populations,
including IDUs, with several prevention measures (education,
condoms, needle exchange) may curb the projected increase in
HIV prevalence in IDUs [3,35].
To further verify the predictive value of our model, we
initialized it with epidemic and behavioral data from mid-2005
(IDU behavioral data are not available for prior years) [3,4,16,41]
and compared the predicted outputs for the end of 2007 with the
reported data we used to obtain the rest of the results in this paper
(Table 4). Adjusting only for the lower rates of treatment
availability and condom usage in 2005 [3], our model accurately
matched several epidemic measures for 2.5 y later: proportion of
population that is IDU, HIV prevalence in IDUs, HIV prevalence
in the general population, overall incidence of HIV, and
proportion of new infections occurring because of IDU versus
heterosexual transmission.
Health Outcomes and Costs
For each scenario we measured costs and QALYs, discounted at
3% annually, over a 20-y time horizon. We included all costs and
QALYs accruing over the time horizon as well as future
discounted lifetime health-related costs and QALYs for all
individuals in the population at the end of the horizon.
We assumed that quality of life decreased with HIV disease
progression. IDUs had a lower quality of life than non-IDUs by a
multiplicative factor of 0.9 (Table S3) [23,33,34,38]. Receiving
ART increased quality of life by 10% of the difference between
untreated and uninfected individuals, accounting for both benefits
Figure 1. Evolution of estimated HIV prevalence among IDUs in Ukraine for various strategies to expand methadone substitution
therapy and ART access. Status quo, no methadone substitution therapy slots, 10% of eligible non-IDUs on ART, 2% of eligible IDUs on ART; Mod
meth, 12.5% of IDUs on methadone substitution therapy, ART according to status quo except 25% of eligible IDUs on methadone substitution
therapy on ART; Hi meth, 25% of IDUs on methadone substitution therapy, ART according to status quo except 25% of eligible IDUs on methadone
substitution therapy on ART; Mod mix, 3.1% of IDUs on methadone substitution therapy, 50% of all eligible patients on ART; Hi tx, no methadone
substitution therapy slots, 80% of all eligible patients on ART; Hi meth, Hi tx, 25% of IDUs on methadone substitution therapy, 80% of all eligible
patients on ART.
doi:10.1371/journal.pmed.1000423.g001
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increased quality of life by 50% of the difference between an
IDU and a non-IDU with the same disease stage and ART
treatment status [38,46].
We based our estimates of the annual costs of methadone
substitution therapy on reports from Ukraine to be US$168, with
US$200 in additional counseling and program support costs
[33,36]. We estimated annual ART cost to be US$450, with
another US$500 for counseling and improving adherence
(unpublished data) [33,47,48]. For individuals receiving both
methadone substitution therapy and ART, we assumed that total
annual counseling and program cost was US$500. All individuals
incurred an annual health care cost of US$310 [16]. HIV-infected
individuals incurred an additional US$1,200 in annual HIV-
related health care costs [3].
Results
Under the status quo, 33,700 new HIV infections occurred over
20 y, with 18,000 in IDUs and 15,700 in non-IDUs.
HIV Infections Prevented
As expected, the ‘‘high methadone substitution therapy, high
ART’’ scenario would avert the most infections (8,300, with 3,630
averted among IDUs and 4,670 among non-IDUs) (Figure 3;
Table 5). After this, the ‘‘high methadone substitution therapy’’
scenario averted the most infections (4,700), with the majority
(2,970) averted among IDUs. This strategy averted 1,730
infections in non-IDUs because of reductions in sexual transmis-
sion from IDUs. The ‘‘high ART’’ scenario averted 4,080
infections (3,350 among non-IDUs).
Figure 2. Evolution of estimated HIV prevalence among non-IDUs in Ukraine for various strategies to expand methadone
substitution therapy substitution therapy and ART access. Status quo, no methadone substitution therapy slots, 10% of eligible non-IDUs on
ART, 2% of eligible IDUs on ART; Mod meth, 12.5% of IDUs on methadone substitution therapy, ART according to status quo except 25% of eligible
IDUs on methadone substitution therapy on ART; Hi meth, 25% of IDUs on methadone substitution therapy, ART according to status quo except 25%
of eligible IDUs on methadone substitution therapy on ART; Mod mix, 3.1% of IDUs on methadone substitution therapy, 50% of all eligible patients
on ART; Hi tx, no methadone substitution therapy slots, 80% of all eligible patients on ART; Hi meth, Hi tx, 25% of IDUs on methadone substitution
therapy, 80% of all eligible patients on ART.
doi:10.1371/journal.pmed.1000423.g002
Table 4. Model calibration, validation parameters, and sources.
Parameter Model Estimate
Reported Value
(2007) Source
Proportion of the population
that is an IDU
1.60% 1.60% [4]
HIV prevalence among IDUs 40.88% 41.20% [3,4]
Overall HIV prevalence 1.62% 1.63% [3,4]
Yearly HIV incidence
per 100,000 persons
233 190–266 (38) Real incidence is unknown, but the officially reported numbers (in parentheses) are
multiplied by a factor of 5–6 to obtain more accurate estimates.
Proportion of new infections
from IDU
51.7% 51% [3]
doi:10.1371/journal.pmed.1000423.t004
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scaled up with a small level of nonlinearity: the ‘‘moderate
methadone substitution therapy’’ scenario prevented slightly
more than four times as many infections as the ‘‘low methadone
substitution therapy’’ scenario (2,120 versus 490). The ‘‘high
methadone substitution therapy’’ scenario prevented slightly
more than twice as many infections as the ‘‘moderate
methadone substitution therapy’’ scenario (4,700 versus 2,120)
owing to the increased reduction in the risk of acquiring
infection from the high-prevalence IDU population. Approxi-
mately 40% of the infections averted in each scenario were
among non-IDUs.
For the ART-only strategies, 80%–85% of infections averted
were in non-IDUs. Since ART reduces the risk of HIV
transmission but still allows a residual level of infectivity, treatment
scale-up offered less than proportional benefits. The ‘‘moderate
ART’’ scenario averted 2,970 infections, approximately 2.4 times
as many as the ‘‘low ART’’ scenario (1,240) instead of the expected
2.5 times.
The incremental 500 methadone substitution therapy slots
from ‘‘low ART’’ to ‘‘low mixed’’ (both offer ART to 20% of
eligible patients, but the ‘‘mixed’’ scenario additionally has 500
methadone substitution therapy slots) increased the number of
averted infections by 36%, from 1,240 to 1,690. More than 35%
of the additional infections averted were in non-IDUs. Similarly,
the ‘‘moderate mixed’’ scenario increased the number of averted
infections versus ‘‘moderate ART’’ by 15%, from 2,970 to
3,410. Infections averted in the mixed scenarios were less than
the sum of the individual interventions, since the same infection
cannot be prevented twice for an individual who benefits
(directly or indirectly) from both methadone substitution
therapy and ART.
The scenario with ‘‘limited ART’’ access to IDUs averted only
1,800 infections (100 among IDUs), less than half the infections
averted in the ‘‘high ART’’ scenario.
HIV Prevalence
Under the status quo, we estimated that HIV prevalence will
decrease from 1.63% to 1.44% in 20 y, because of high AIDS
mortality and the natural epidemic evolution (Table 5). However,
with the reported level of IDU risky behaviors and the relatively
high reported condom usage [24], which limits heterosexual HIV
transmission, HIV prevalence is expected to grow among IDUs
from 41.2% to 67.2% (Figure 1), and decrease among non-IDUs
from 0.99% to 0.88% (Figure 2).
For methadone substitution therapy-focused strategies, preva-
lence decreased among IDUs (Figure 1) and non-IDUs (Figure 2)
in inverse proportion to the number of methadone substitution
therapy slots: in the ‘‘moderate methadone substitution therapy’’
and ‘‘high methadone substitution therapy’’ scenarios, prevalence
decreased, respectively, to 0.85% and 0.80% among non-IDUs,
and 61.0% and 53.1% in IDUs. Because ART prolongs the lives of
infected individuals, allowing them to remain longer in the
population, the ART-focused strategies led to slight increases in
HIV prevalence among IDUs and non-IDUs, even though HIV
infections were averted.
Figure 3. Estimated number of HIV infections averted over 20 y among IDUs and non-IDUs for strategies to expand methadone
substitution therapy and ART access in Ukraine. Low meth, 3.1% of IDUs on methadone substitution therapy, ART according to status quo
except 25% of eligible IDUs on methadone substitution therapy on ART; Mod meth, 12.5% of IDUs on methadone substitution therapy, ART
according to status quo except 25% of eligible IDUs on methadone substitution therapy on ART; Hi meth, 25% of IDUs on methadone substitution
therapy, ART according to status quo except 25% of eligible IDUs on methadone substitution therapy on ART; Low mix, 3.1% of IDUs on methadone
substitution therapy, 20% of eligible non-IDUs and IDUs not on methadone substitution therapy on ART, 25% of IDUs on methadone substitution
therapy on ART; Mod mix, 3.1% of IDUs on methadone substitution therapy, 50% of all eligible patients on ART; Low tx, no methadone substitution
therapy slots, 20% of all eligible patients on ART; Mod tx, no methadone substitution therapy slots, 50% of all eligible patients on ART; Hi tx, no
methadone substitution therapy slots, 80% of all eligible patients on ART; Limited tx, no methadone substitution therapy slots, 80% of eligible non-
IDUs on ART, 10% of eligible IDUs on ART; Hi meth, hi tx, 25% of IDUs on methadone substitution therapy, 80% of all eligible patients on ART.
doi:10.1371/journal.pmed.1000423.g003
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Due to cost differences, the methadone substitution therapy
strategies were less expensive than the corresponding ART
strategies, while offering significant benefits (Figure 4; Table 5).
If all methadone substitution therapy scenarios are feasible in
practice, the most cost-effective strategy is scaling up methadone
substitution therapy as much as possible (Figure 4). The ‘‘high
methadone substitution therapy’’ scenario costs US$530/QALY
gained (confidence interval [CI] US$250–US$930/QALY gained)
compared to the status quo. The most effective strategy is ‘‘high
methadone substitution therapy, high ART’’ which costs
US$1,120/QALY gained (CI US$770–US$1370/QALY gained)
compared to the ‘‘high methadone substitution therapy’’ strategy.
This strategy also has the highest total cost (Figure 4). The next
most effective alternative is the ‘‘high ART’’ scenario, which has
modestly lower total costs, but is less efficient at US$2,240/QALY
gained (CI: US$940–US$4,070) compared to the ‘‘high metha-
done substitution therapy’’ strategy. According to World Health
Organization (WHO) guidelines [49,50], these strategies are all
highly cost-effective because they cost less than Ukraine’s per
capita gross domestic product (GDP). The ‘‘mixed’’ scenarios and
‘‘low ART’’ and ‘‘moderate ART’’ scenarios were dominated
(they cost more and generated fewer QALYs than other strategies
or combinations of strategies), as was the ‘‘limited ART’’ scenario.
Given practical considerations and political reluctance to invest
in programs directed to IDUs, we evaluated the cost effectiveness
of the alternatives assuming that only the minimal level of
methadone substitution therapy can be implemented (Figure 5).
Under these constraints, the ‘‘low methadone substitution
therapy’’ strategy is the most cost-effective alternative, with an
incremental cost/QALY gained of US$650 (CI US$310–
US$1,100) compared to the status quo. A more effective but
more expensive option is the ‘‘low mixed’’ scenario (US$1,030/
QALY gained, CI US$670–US$1,270), followed by the ‘‘moderate
mixed’’ scenario (US$1,130/QALY gained, CI US$780–
US$1,390), and the ‘‘high ART’’ scenario (US$1,280/QALY
gained, CI US$810–US$1,600), all of which are considered highly
cost effective by international standards [49,50].
Sensitivity Analyses
We performed one-way sensitivity analyses on all model
parameters (Figure S2 and Table S5 summarize the key results
for the ‘‘high methadone substitution therapy’’ scenario), and
select multiway sensitivity analyses. The main parameters affecting
infections averted were related to risky sexual and injecting
behaviors, methadone substitution therapy effectiveness in reduc-
ing injecting-related risks, ART effectiveness in reducing infectiv-
ity, and the infectivity of unsafe sexual and equipment-sharing
contacts. In all cases, the relative differences between the scenarios
remained comparable to the base case, with the same alternatives
being preferred. We discuss here only the most important findings
from the sensitivity analyses.
Figure 4. Cost effectiveness of various strategies for scaling up methadone substitution therapy and ART access in Ukraine,
assuming that scaling up methadone substitution therapy is a feasible option. Status quo, no methadone substitution therapy slots, 10%
of eligible non-IDUs on ART, 2% of eligible IDUs on ART; Low meth, 3.1% of IDUs on methadone substitution therapy, ART according to status quo
except 25% of eligible IDUs on methadone substitution therapy on ART; Mod meth, 12.5% of IDUs on methadone substitution therapy, ART
according to status quo except 25% of eligible IDUs on methadone substitution therapy on ART; Hi meth, 25% of IDUs on methadone substitution
therapy, ART according to status quo except 25% of eligible IDUs on methadone substitution therapy on ART; Low mix, 3.1% of IDUs on methadone
substitution therapy, 20% of eligible non-IDUs and IDUs not on methadone substitution therapy on ART, 25% of IDUs on methadone substitution
therapy on ART; Mod mix, 3.1% of IDUs on methadone substitution therapy, 50% of all eligible patients on ART; Low tx, no methadone substitution
therapy slots, 20% of all eligible patients on ART; Mod tx, no methadone substitution therapy slots, 50% of all eligible patients on ART; Hi tx, no
methadone substitution therapy slots, 80% of all eligible patients on ART; Limited tx, no methadone substitution therapy slots, 80% of eligible non-
IDUs on ART, 10% of eligible IDUs on ART; Hi meth, Hi tx, 25% of IDUs on methadone substitution therapy, 80% of all eligible patients on ART.
doi:10.1371/journal.pmed.1000423.g004
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parameters (Table S4): reduction in infectivity due to ART,
methadone substitution therapy effectiveness in reducing equip-
ment sharing, IDU preference for other IDUs as sexual partners,
and ART costs. We varied the reduction in sexual and injection
sharing infectivity owing to ART and found that our results were
generally robust. For the ‘‘high ART’’ scenario, if ART reduces
infectivity of risky IDU contacts by 90% (base case 50%), 5,000
infections are averted (versus 4,080 in the base case). If ART only
reduces sexual infectivity by 50% (base case 90%), only 1,790
infections are averted. However, these differences do not change
the relative cost effectiveness of the strategies.
We varied the efficacy of methadone substitution therapy in
reducing risky injection behavior. We found that ‘‘high methadone
substitution therapy’’ prevents more infections than ‘‘high ART’’ if
methadone substitution therapy decreases equipment sharing by at
least 70%. If the decrease is 60% (versus 85% in the base case),
‘‘high methadone substitution therapy’’ still averts 3,230 infec-
tions, versus 4,700 in the base case. This finding is significant
because information about the effectiveness of methadone
substitution therapy programs in Ukraine is limited. Pilot
programs with buprenorphine showed potential reductions in
risky behaviors to a minimal level, and significant improvements in
the quality of life of IDUs undergoing substitution therapy [11].
These data (significant reductions in risky behaviors and
improvements in quality of life) are consistent with the results of
other substitution therapy pilot programs in Eastern Europe
(Poland, Lithuania) [46]. However, IDUs participating in the pilot
programs may be the most committed to changing risky behavior,
and results may change with program expansion.
Because there is uncertainty about behavioral risk parameters,
we varied the percentage of sexual partners of IDUs who are also
IDUs from 20% to 70% (base case 45%). We found that ‘‘high
methadone substitution therapy’’ (which averts 4,700 infections in
the base case) averts more infections than ‘‘high ART’’ in both
cases (6,260 versus 4,960 for 20% preference and 3,380 versus
3,070 for 70% preference).
There is relatively clear information on the costs of methadone
substitution therapy in Ukraine, but little information on ART
costs. We varied the price of ART and related services between
US$250 and US$2,000 and found that, while the total cost of ART
scenarios varied, their relative rankings in terms of cost
effectiveness stayed the same.
Our base case assumed constant costs per person reached by an
intervention, regardless of program scale. However, as interven-
tions scale up, the cost per person reached may increase (e.g., as
programs scale up, it may become more expensive to enroll and
retain individuals because of increasing outreach and adherence
costs). To evaluate this possibility, in sensitivity analysis we
assumed a 20% higher cost per person for scenarios involving
‘‘high methadone substitution therapy’’ or ‘‘high ART.’’ In this
case, ‘‘moderate methadone substitution therapy’’ became slightly
Figure 5. Cost effectiveness of various strategies for scaling up methadone substitution therapy and ART access in Ukraine,
assuming that only a low level of methadone substitution therapy (3.1% of IDUs on methadone substitution therapy) is feasible.
Status quo, no methadone substitution therapy slots, 10% of eligible non-IDUs on ART, 2% of eligible IDUs on ART; Low meth, 3.1% of IDUs on
methadone substitution therapy, ART according to status quo except 25% of eligible IDUs on methadone substitution therapy on ART; Mod meth,
12.5% of IDUs on methadone substitution therapy, ART according to status quo except 25% of eligible IDUs on methadone substitution therapy on
ART; Hi meth, 25% of IDUs on methadone substitution therapy, ART according to status quo except 25% of eligible IDUs on methadone substitution
therapy on ART; Low mix, 3.1% of IDUs on methadone substitution therapy, 20% of eligible non-IDUs and IDUs not on methadone substitution
therapy on ART, 25% of IDUs on methadone substitution therapy on ART; Mod mix, 3.1% of IDUs on methadone substitution therapy, 50% of all
eligible patients on ART; Low tx, no methadone substitution therapy slots, 20% of all eligible patients on ART; Mod tx, no methadone substitution
therapy slots, 50% of all eligible patients on ART; Hi tx, no methadone substitution therapy slots, 80% of all eligible patients on ART; Limited tx, no
methadone substitution therapy slots, 80% of eligible non-IDUs on ART, 10% of eligible IDUs on ART; Hi meth, Hi tx, 25% of IDUs on methadone
substitution therapy, 80% of all eligible patients on ART.
doi:10.1371/journal.pmed.1000423.g005
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done substitution therapy’’ (US$660/QALY gained versus ‘‘mod-
erate methadone substitution therapy’’), but both programs were
highly cost effective.
To further test the robustness of our model, we performed a
probabilistic sensitivity analysis (details in Text S1). We used the
results from the simulation to construct 95% CIs for the number of
infections averted in each strategy, and found that the mean values
from the probabilistic sensitivity analysis matched the values and
the trends we observed in the base case analyses (Table 6).
Discussion
Our analyses showed that the methadone substitution therapy-
focused scenarios are the most cost effective, and that benefits
increase with the scale of the project, even among non-IDUs. The
most effective intervention is to provide high levels of methadone
substitution therapy and ART, a strategy that is also economically
efficient. Providing as much methadone substitution therapy as is
possible is desirable, since methadone substitution therapy
enhances the effects of ‘‘ART only’’ programs and helps prevent
additional infections, even among non-IDUs. Importantly, we
found that substitution therapy averted the most infections, but
expanded ART along with expanded substitution therapy
provided the largest total increase in QALYs. This result highlights
the complementary nature of these interventions.
We analyzed the cost effectiveness of combinations of two
important interventions that may potentially compete for scarce
resources—harm reduction and treatment scale up. Given the
importance of these interventions in controlling HIV, analyzing
their use in combination and assessing the synergies between them
is an important first step in making decisions about portfolios of
prevention and treatment interventions in a mixed epidemic. We
evaluated the cost effectiveness of these programs in Ukraine,
which has one of the fastest growing HIV epidemics in the world
and the highest prevalence in Europe. Its mixed epidemic is driven
largely, but not exclusively, by injection drug use. The success or
failure of strategies to mitigate the epidemic in Ukraine is
substantial, as such strategies may be applicable to the region
more broadly.
Our finding that methadone substitution therapy, even at
modest levels, can substantially reduce new HIV infections and
HIV prevalence is particularly significant given the importance of
injection drug use in the spread of HIV in Eastern Europe, Russia,
Table 6. Results of probabilistic sensitivity analysis.
Analysis
Status
Quo
Low
Methadone
Substitution
Therapy
Moderate
Methadone
Substitution
Therapy
High
Methadone
Substitution
Therapy
Low
Mixed
Moderate
Mixed
Low
ART
Moderate
ART
High
ART
Limited
ART
High
Methadone
Substitution
Therapy,
High ART
Infections
averted
Deterministic
model
0 490 2,120 4,700 1,690 3,410 1,240 2,970 4,080 1,800 8,300
Simulation
average
0 480 2,050 4,510 1,910 3,920 1,480 3,500 4,770 2,150 8,710
95% CI 280–710 1,260–3,000 2,910–6,450 1,310–
2,600
2,630–
5,380
950–
2,130
2,290–
4,940
3,120–
6,680
1,290–
3,140
6,240–11,480
HIV
prevalence
overall
Deterministic
model
1.44% 1.43% 1.38% 1.29% 1.44% 1.49% 1.46% 1.50% 1.53% 1.57% 1.38%
Simulation
average
1.48% 1.47% 1.42% 1.33% 1.47% 1.50% 1.48% 1.51% 1.53% 1.59% 1.39%
95% CI 1.09%–1.91% 1.07%–1.89% 1.02%–1.85% 0.93%–1.76% 1.07%–
1.89%
1.09%–
1.92%
1.09%–
1.90%
1.10%–
1.93%
1.12%–
1.95%
1.18%–
2.04%
0.97%–1.83%
HIV prevalence,
IDUs
Deterministic
model
67.3% 65.8% 61.0% 53.1% 65.7% 65.6% 67.1% 67.0% 66.9% 67.1% 53.7%
Simulation
average
65.4% 64.0% 59.3% 51.9% 63.8% 63.5% 65.1% 64.8% 64.6% 65.2% 52.1%
95% CI 44.7%–79.4% 43.5%–78.3% 37.6%–74.7% 30.1%–68.7% 42.7%–
78.1%
41.2%–
78.3%
44.4%–
79.4%
42.9%–
79.4%
42.4%–
79.6%
44.4%–
79.4%
29.2%–70.1%
QALYs (1,000s)
Deterministic
model
32,749 32,758 32,785 32,825 32,788 32,839 32,780 32,831 32,863 32,826 32,930
Simulation
average
32,849 32,857 32,884 32,923 32,891 32,945 32,883 32,937 32,971 32,930 33,036
95% CI 29,516–
36,447
29,524–
36,457
29,549–
36,485
29,584–
36,524
29,543–
36,500
29,578–
36,568
29,535–
36,492
29,572–
36,560
29,600–
36,602
29,566–
36,550
29,663–36,664
doi:10.1371/journal.pmed.1000423.t006
Harm Reduction and ART in Ukraine
PLoS Medicine | www.plosmedicine.org 11 March 2011 | Volume 8 | Issue 3 | e1000423and Central Asia. Although our quantitative estimates of cost
effectiveness cannot be generalized to other countries, harm
reduction and substitution therapy will likely be critical to the
control of HIV throughout the region.
Ukraine’s decision to invest in ART and methadone substitution
therapy programs could be highly economically efficient. WHO
guidelines define interventions that cost less than the per capita
gross domestic product (GDP) as highly cost effective [49,50]. The
per capita GDP of Ukraine was approximately US$7,000 in 2008.
Hence, expansion of substitution therapy, and ART alone or in
addition to methadone substitution therapy, is highly cost effective.
One other study found HIV interventions targeted to IDUs in
Ukraine to be cost effective [24], but their results are not
comparable to ours because that study considered different
interventions (provision of condoms, syringes, and information
materials, peer education, but not HIV treatment), focused only in
the city of Odessa, and measured the costs per infection averted
from the provider’s perspective.
Neglecting IDUs in national programs or providing insufficient
outreach to attract and retain them in treatment programs can
undermine HIV control efforts [33]. Even if 80% of eligible non-
IDUs are treated, if IDUs have minimal access to ART, only half
as many infections are averted among non-IDUs, because of
sexual transmission from untreated IDUs. These results highlight
the importance of Ukraine’s commitment to address HIV among
IDUs [3].
ART costs have decreased in recent years, even if the results of
price negotiations have not always been fully implemented in
practice (unpublished data) [47]. Further progress in lowering
prices may occur if plans to involve local producers succeed.
However, our analysis showed that even with an ART price of
US$250, methadone substitution therapy-focused strategies have
more favorable cost-effectiveness ratios than do ART-only
strategies.
We estimated the benefits of methadone substitution therapy
conservatively, assuming successful ‘‘graduation’’ was only 5%.
Long-term follow-up from the buprenorphine pilot program in
Ukraine is not yet available, but preliminary data suggest higher
graduation rates [11], which would make methadone substitution
therapy more cost effective. Additionally, we assumed that all
IDUs have similar preference for IDU sexual partners, regardless
of methadone substitution therapy status, which may change once
individuals on methadone substitution therapy are committed to
behavior changes.
While some HIV cost-effectiveness studies use disability-adjusted
life years (DALYs) to measure health outcomes, we used QALYs to
measure health outcomes, following recommendations for the
conduct of cost-effectiveness analysis [51,52]. QALY weights reflect
quality of life in health states. DALYs were designed to evaluate the
burden of disease in countries [53–55]. Our results are not likely to
changequalitativelyifDALYsareusedtomeasurehealthoutcomes,
as both measures reflect morbidity associated with disease.
Our analysis has several limitations. We assumed homogeneous
mixing between individuals in all compartments, which means that
the probability of having a risky contact with an individual from a
compartment depends only on the relative size of the compart-
ment. The only exception is preferential sexual mixing by IDUs
(an estimated 45% of sexual contacts are shared with other IDUs
[10,12,24,33,40]). The homogeneous mixing assumption may not
hold in practice, since IDUs are often involved in sexual and
needle-sharing networks with other drug injectors, rather than
mixing randomly. Methadone substitution therapy programs that
reach IDUs central in such networks will be most effective in
reducing HIV transmission. Also, we assumed that our parameters
apply to the whole population, whereas in reality the epidemic
characteristics vary across the country.
Data about the HIV epidemics in Ukraine, Eastern Europe, and
Central Asia, in particular cost information, are limited and
change rapidly. Our sensitivity analyses showed that the scenario
choices are unchanged over a wide variety of parameters, but the
cost-effectiveness ratios may change. More information is needed
about the effectiveness of methadone substitution therapy
programs in this region as well as potential economies or
diseconomies of scale as methadone substitution therapy and
ART programs are scaled up from their current low levels.
Our analyses evaluated the effectiveness, total expenditures, and
efficiency of the strategies we considered. How policymakers
choose among the alternatives we evaluated may also depend on
whether there are constraints on the total budget available for such
programs, which in turn depends on how policymakers prioritize
interventions related to HIV relative to interventions for other
health conditions, and to nonhealth spending. For example,
implementation of the high levels of methadone substitution
therapy and ART would require total expenditures of US$150
million over 20 y, while implementation of the high methadone
substitution therapy-only strategy, although less effective, requires
total expenditures of under US$50 million.
In conclusion, we have shown that methadone substitution
therapy is a highly cost-effective option for addressing the growing
HIV epidemic in Ukraine. A strategy that expands both
methadone substitution therapy and ART to high levels is the
most effective intervention, as the two interventions are comple-
mentary and synergistic. Such a strategy is very cost effective by
WHO criteria. For programs that primarily expand ART,
provision of minimal access to methadone substitution therapy
provides additional benefit in terms of number of infections
averted. Because the HIV epidemic in Ukraine is representative of
the HIV epidemic in Eastern Europe and Central Asia, our
analyses are relevant for decision makers faced with a mixed
epidemic in this region.
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Background HIV epidemics in Eastern Europe and Central
Asia are mainly driven by increasing use of injection drugs
combined with heterosexual transmission. In the Ukraine, in
2007, there were 82,000 officially registered people living
with HIV—three times the number registered in 1999—and
an estimated 395,000 HIV infected adults. The epidemic in
Ukraine, like other countries in the region, is concentrated in
at-risk populations, particularly people who inject drugs: in
2007, an estimated 390,000 Ukrainians were injecting drugs,
an increase in drug use over the previous decade, not only in
Ukraine, but in other former USSR states, owing to the easy
availability of precursors for injection drugs in a climate of
economic collapse.
The common practices of people who inject drugs in Ukraine
and in other countries in the region, such as social injecting,
syringe sharing, and using common containers, increase the
risk of transmitting HIV. Public health interventions such as
needle exchange can limit these risk factors and have been
gradually implemented in these countries. In 2007, Ukraine
approved the use of methadone substitution therapy and
the current target is for 11,000 people who inject drugs to be
enrolled in substitution therapy by 2011. Furthermore, since
treatment for HIV-infected individuals is also necessary,
national HIV control plans included a target of 90%
antiretroviral therapy (ART) coverage by 2010 but in 2007
less than 10% of the 91,000 eligible people received
treatment. Although the number of people who inject drugs
and who receive ART is unknown, physicians are often
reluctant to treat people who inject drugs using ART owing
to alleged poor compliance.
Why Was This Study Done? As resources for HIV
interventions in the region are limited, it is important to
investigate the appropriate balance between investments in
methadone substitution therapy and ART in order to
maximize benefits to public health. Several studies have
analyzed the cost effectiveness of methadone substitution
therapy in similar settings but have not considered tradeoffs
between ART and methadone substitution therapy.
Therefore, to provide insights into the appropriate public
health investment in methadone substitution therapy and
ART in Ukraine, the researchers evaluated the public health
effectiveness and cost effectiveness of different strategies
for scaling up methadone substitution therapy and/or
expanding ART.
What Did the Researchers Do and Find? The researchers
developed a model to accommodate different population
groups: people who inject drugs on substitution therapy
with methadone; people who inject opiates and do not take
any substitution therapy; and people who do not inject any
drugs, hence do not need substitution therapy. The
researchers inputted Ukraine country-level data into this
model and used current HIV trends in Ukraine to make
rational assumptions on possible future trends and scenarios.
They considered scenarios expanding methadone
substitution therapy availability, increasing acces to ART, or
both. Then, the researchers measured health care costs,
quality-adjusted life years (QALYs), HIV prevalence, infections
averted, and incremental cost effectiveness for the different
scenarios. They found that after 20 years, HIV prevalence
reached 67.2% in people who inject drugs and 0.88% in
people who do not inject drugs without further
interventions. Offering methadone substitution therapy to
25% of people who inject drugs was the most effective
strategy in reducing prevalence of HIV and was also the most
cost effective, averting 4,700 infections and adding 75,700
QALYs versus the status quo at $530/QALY gained.
Expanding both methadone substitution therapy and ART
was also a highly cost effective option, adding 105,000
QALYs at US$1,120/QALY gained versus the methadone
substitution therapy-only strategy. Offering ART to 80% of
eligible people who did not inject drugs, and 10% of people
who injected drugs averted only 1,800 infections, and added
76,400 QALYs at $1,330/QALY gained.
What Do These Findings Mean? The results show that
methadone substitution-focused therapeutic scenarios are
the most cost effective, and that benefits increase with the
scale of the project, even among people who do not inject
drugs. This makes a methadone substitution strategy a
highly cost-effective option for addressing the growing HIV
epidemic in Ukraine. Therefore, if it is not feasible to invest in
large-scale methadone substitution programs for any reason,
political circumstances for example, providing as much
methadone substitution as is acceptable is still desirable.
While substitution therapy appears to avert the most HIV
infections, expanded ART provides the largest total increase
in QALYs. Thus, methadone substitution therapy and ART
offer complementary benefits. Because the HIV epidemic in
Ukraine is representative of the HIV epidemic in Eastern
Europe and Central Asia, the cost-effective strategies that the
researchers have identified may help inform all decision
makers faced with a mixed HIV epidemic.
Additional Information Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1000423.
N Alliance provides information on its work supporting
community action on AIDS in Ukraine
N USAID provides an HIV/AIDS Health Profile for Ukraine
N UNICEF provides information about its activities to help
Ukraine fight rising HIV/AIDS infection rates
N International Harm Reduction Association provides infor-
mation about the status of harm reduction interventions
such as methadone substitution therapy around the world
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